Cromolyn modifies histamine bronchial reactivity in symptomatic seasonal asthma

Sixteen adults with symptomatic seasonal asthma were treated with either cromolyn or placebo during the pollen season, in a double blinded fashion. Over the study time (three months) bronchial histamine tolerance increased in the treated group while decreasing in the placebo group (P less than .002 at three months). Other measurements, such as FEV1, PEFR and symptom scores supported the idea that cromolyn therapy benefitted the course of seasonal asthma.